Key result
CRISPR-Cas13a strongly inhibits HIV-1 infection in human cells by destroying viral RNA.
Why the study?
CRISPR-Cas13a has potential to inhibit HIV-1 infection by targeting viral RNA, but its efficacy in human cells was not established.
CRISPR-Cas13a can be repurposed to target and destroy HIV-1 RNA, offering a potential novel tool for treating viral diseases.
CRISPR-Cas13a inhibits HIV-1 via RNA targeting; leaves open whether this extends to clinical antiviral strategies.
CRISPR-Cas provides bacteria and archaea with immunity against invading phages and foreign plasmid DNA and has been successfully adapted for gene editing in a variety of species. The class 2 type VI CRISPR-Cas effector Cas13a targets and cleaves RNA, providing protection against RNA phages. Here we report the repurposing of CRISPR-Cas13a to inhibit human immunodeficiency virus type 1 (HIV-1) infection through targeting HIV-1 RNA and diminishing viral gene expression. We observed strong inhibition of HIV-1 infection by CRISPR-Cas13a in human cells. We showed that CRISPR-Cas13a not only diminishes the level of newly synthesized viral RNA, either from the transfected plasmid DNA or from the viral DNA, which is integrated into cellular DNA, but it also targets and destroys the viral RNA that enters cells within viral capsid, leading to strong inhibition of HIV-1 infection. Together, our results suggest that CRISPR-Cas13a provides a potential novel tool to treat viral diseases in humans.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2020) studied HIV-1 infection. CRISPR-Cas13a was evaluated on HIV-1 infection and viral RNA levels. CRISPR-Cas13a strongly inhibited HIV-1 infection in human cells by targeting and destroying viral RNA and diminishing viral gene expression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: